Dear Healthcare Professionals,
As an update to our July report on SGLT2 inhibitors and the GlycoMark 1,5-AG test, we are pleased to summarize new data presented at the ADA Advancing Precision Diabetes Medicine meeting in October. In the study “GlycoMark 1,5-Anhydroglucitol as a Biomarker of SGLT2 Inhibitor Effect”, Dahlen, et al. describe the observed relationship between the GlycoMark 1,5-AG test and the effect of SGLT2 inhibitors.
As shown in Fig 1, patients with diabetes NOT on SGLT2 inhibitor treatment had GlycoMark 1,5-AG test results in the upper ABNORMAL range, indicating recent hyperglycemia and hyperglycemic excursions. Patients with diabetes ON-TREATMENT of an SGLT2 inhibitor had extremely low GlycoMark test results, ≤2 μg/mL, suggesting treatment compliance and desired SGLT2 inhibitor effect.
The optimal cutoff for identifying the SGLT2 inhibitor effect was a GlycoMark result < 2.0 ug/mL, which was validated in an independent dataset and found to have a sensitivity of 92.2% and specificity of 100% for the detection of an SGLT2 inhibitor effect in diabetes patients with A1C < 8% (Table 1).
SGLT2 inhibitors lower glucose levels in patients with diabetes by preventing the kidneys from reabsorbing glucose, triggering glycosuria.2
The GlycoMark test, a measure of 1,5-anhydroglucitol (1,5-AG), is highly sensitive to glycosuria and is used to detect recent hyperglycemia and hyperglycemic excursions. (Abnormal <10 μg/mL). The GlycoMark test is not specifically indicated to detect or measure the presence of SLGT-2 inhibitors.
Dr. Jeff Dahlen is VP of Clinical and Scientific Affairs at GlycoMark.
1Dahlen JR, et al. GlycoMark 1,5-Anhydroglucitol as a Biomarker of SGLT2 Inhibitor Effect. Poster presented at the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium, October 2019, Madrid, Spain.
2Garber AJ, et al. 2018 AACE/ACE T2D Management, Endocr Pract. 2018;24(No. 1).